Research programme: photodynamic therapy - Theralase/UHN/OCE

Drug Profile

Research programme: photodynamic therapy - Theralase/UHN/OCE

Alternative Names: TLC-3000 project

Latest Information Update: 29 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theralase Technologies
  • Class
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Mar 2012 Pharmacodynamics data from preclinical studies released by Theralase Technologies
  • 09 Nov 2010 Theralase Technologies commences animal toxicology studies of four lead compounds
  • 23 Jul 2007 Preclinical trials in Cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top